{
    "Clinical Trial ID": "NCT00041067",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab, Docetaxel, Vinorelbine and Filgrastim",
        "  Trastuzumab, docetaxel, vinorelbine and filgrastim",
        "  docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles",
        "  vinorelbine : 27.5 mg/m^2 on Days 8 and 15",
        "  filgrastim : 5 microg/kg/day on Days 2 to 21",
        "  trastuzumab : 4 mg/kg by IV over a 90-minute period on Day 1 of the first cycle, then weekly 2 mg/kg by IV over a 30-minute period"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed stage IV breast cancer",
        "  Metastasis to the ipsilateral supraclavicular lymph nodes allowed",
        "  HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting",
        "  No effusions or ascites as only sites of disease",
        "  No primary or metastatic brain or central nervous system tumor",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  18 and over",
        "  Sex:",
        "  Female",
        "  Menopausal status:",
        "  Not specified",
        "Performance status:",
        "  Zubrod 0-2",
        "  Life expectancy:",
        "  Not specified",
        "  Hematopoietic:",
        "  Absolute neutrophil count at least 1,500/mm^3",
        "  Platelet count at least 100,000/mm^3",
        "  Hepatic:",
        "  Bilirubin normal",
        "  aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)",
        "  Alkaline phosphatase no greater than 2.5 times ULN",
        "  Renal:",
        "  Not specified",
        "  Cardiovascular:",
        "  left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)",
        "  No clinical evidence or history of cardiomyopathy",
        "  Other:",
        "  No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer",
        "  No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission",
        "  No known sensitivity to E. coli-derived proteins",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  Not specified",
        "  Chemotherapy:",
        "  At least 6 months since prior chemotherapy",
        "  Prior anthracycline as adjuvant therapy allowed",
        "  No prior cumulative dose of doxorubicin more than 360 mg/m^2",
        "  No prior cumulative dose of epirubicin more than 720 mg/m^2",
        "  No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease",
        "  No prior docetaxel",
        "  No prior vinorelbine",
        "  Prior paclitaxel allowed",
        "  Endocrine therapy:",
        "  Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed",
        "  No concurrent hormonal therapy",
        "  Radiotherapy:",
        "  At least 3 weeks since prior radiotherapy",
        "  Surgery:",
        "  At least 2 weeks since prior surgery and recovered"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Survival at 1 Year",
        "  [Not Specified]",
        "Time frame: 1 year",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab, Docetaxel, Vinorelbine and Filgrastim",
        "  Arm/Group Description: Trastuzumab, docetaxel, vinorelbine and filgrastim",
        "  docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles",
        "  vinorelbine : 27.5 mg/m^2 on Days 8 and 15",
        "  filgrastim : 5 microg/kg/day on Days 2 to 21",
        "  trastuzumab : 4 mg/kg by IV over a 90-minute period on Day 1 of the first cycle, then weekly 2 mg/kg by IV over a 30-minute period",
        "  Overall Number of Participants Analyzed: 74",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of patients  93        (84 to 97)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/73 (0.00%)"
    ]
}